ValiRx, a drug developer focused on early-stage cancer therapeutics and women's health, has been showing high-beta characteristics. Market data on 24 September 2026 showed a one-yearBetaof 1.42.
IXICO (LSE:IXI) analyses brain scans for pharmaceutical and biotech companies runningClinical Trialsin neurological diseases such as Huntington's, Alzheimer's and Parkinson's. Its shares were among the most volatile UK stocks on 23 September 2026.
Incanthera plc (LSE:INC) was among the most volatile UK stocks on 23 September 2026. Since early June the company has acquired a Swiss skincareBrandfor shares, replaced its chief executive and chairman and, on 7 September, announced an exclusive supply agreement with UK LED skincare …
Cizzle Biotechnology (LSE:CIZ) is a UK diagnostics developer whose lead product is a blood test for the CIZ1B biomarker, which the company says is highly associated with early-stage lung cancer. Its shares were among the most volatile on the UK market on 23 September …
EDX Medical Group plc (LSE:EDX) appeared among the most volatile UK stocks on 23 September 2026. The company's shares began trading on AIM on 13 May 2026 after moving from the Apex segment of the Aquis Stock Exchange Growth Market. This article uses the …
Imaging Biometrics (LSE:IBAI), formerly IQ-AI Limited, featured among the most volatile UK stocks on 23 September 2026. The Jersey-incorporated group develops quantitative MRI software for neuro-oncology through its US subsidiary, Imaging Biometrics LLC, and owns Kirkstall, an organ-on-a-chip business.
Futura Medical plc (LSE:FUM) featured among the most volatile UK stocks on 23 September 2026, the same day shareholders were due to vote on its latest fundraising at a general meeting. The company is quoted on AIM; this article uses the FTSE AIM All-Share …
ImmuPharma plc (LSE:IMM) was among the most volatile UK stocks on 23 September 2026. The company's shares trade on AIM, the London Stock Exchange's growth market.
CRISM Therapeutics (LSE:CRTX) was among the most volatile UK stocks on 23 September 2026. The company is a clinical-stage drug-deliveryBusinessdeveloping ChemoSeed, a biodegradable implant that releases chemotherapy directly into tumour tissue. Its lead target is glioblastoma, an aggressive brain cancer.
CVS (LSE:CVSG) grew by repeating one approach: buy local practices, keep their local identity, and add group-wide purchasing, diagnostics, online retail and a pet health subscription scheme. Simon Innis, chief executive from 2004, oversaw most of the UK roll-up. Richard Fairman, chief executive since …